Given that SOS is a life-threatening complication, any delays or failure to recognize patients at risk can result in detrimental outcomes. The purpose of this activity is to equip pharmacists and pharmacist technicians with the knowledge of the most current updates in the recognition, risk assessment, severity grading, and the management of SOS. In March of 2020, the British Society of Hematology expert group published an update revealing new information on the pathogenesis, modifiable and unmodifiable risk factors for disease development, along with new revised diagnostic criteria, grading classification for SOS, and the evidence on the use of different prophylactic and therapeutic modalities. The early identification of the risk factors, more timely and accurate diagnosis and more innovative treatment approaches are crucial elements in improving patient survival. This presentation will summarize the new updates on SOS management and review the primary literature behind the newly published recommendations.